shutterstock-384260263
ALIM YAKUBOV / SHUTTERSTOCK.COM
7 June 2016PharmaAndré Guder

Protecting homeopathic treatments in Europe

Little case law is available which could shed light on the position of the European Patent Office (EPO) on patentability of homeopathic medicaments. In particular, it has been questionable whether the requirements of sufficiency of disclosure laid down in article 83 of the European Patent Convention (EPC) can be regarded as fulfilled if the invention relates to a homeopathic compound that is administered in dilutions which go beyond the Avogadro level, ie, dilutions which statistically do not contain a single molecule of the potentially active compound.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
27 August 2026   Turkish regulators are investigating the drugmaker over its efforts to protect its drug from generic rivals—conduct that may sound familiar to European competition watchers.
Pharma
21 August 2026   Under the terms of the agreement, which resolves all patent litigation between the biopharma rivals, Teva now has a launch date for its own version of Aurinia's Lupkynis.
Pharma
20 August 2026   A reported deal with an Indian manufacturer could clear a path for a future generic launch as the Korean drugmaker leverages one of its biggest US products.